ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

DTIC-DOME
Leukemias, lymphomas, and other hematologic cancers
Melanoma and other skin cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

REMOVE SELECTED | COMPARE SELECTED

Drug Name:

DTIC-DOME Rx

Generic Name and Formulations:
Dacarbazine 200mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol.

Company:
Bayer Healthcare Pharmaceuticals Inc.

e-Prescribe this drug via Surescripts


Therapeutic Use:

Product Resources »
  • Product Information
  • Coupons, Samples & Vouchers
  • Patient Education and Assistance

Indications for DTIC-DOME:

Metastatic malignant melanoma. Second-line therapy for Hodgkin's disease, in combination with other agents.

Adult Dose for DTIC-DOME:

Give by IV infusion. Malignant melanoma: 2–4.5mg/kg/day for 10 days, may repeat every 4 weeks; or 250mg/m2 daily for 5 days, may repeat every 3 weeks. Hodgkin's disease (in combination with other drugs): 150mg/m2 daily for 5 days, may repeat every 4 weeks; or 375mg/m2 on day 1, then repeat every 15 days.

Children's Dose for DTIC-DOME:

Not recommended.

Pharmacological Class:

Alkylating agent.

Warnings/Precautions:

Monitor CBCs, platelets; may need to discontinue or suspend therapy if hemopoietic toxicity occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.

Adverse Reactions:

Myelosuppression (eg, leukopenia, thrombocytopenia, anemia), anorexia, nausea, vomiting, flu-like syndrome, alopecia, facial flushing/paresthesia, inj site reactions, anaphylaxis; rare: hepatic necrosis, photosensitivity reactions.

How Supplied:

Vials (20mL)—12

Indications for DTIC-DOME:

Metastatic malignant melanoma. Second-line therapy for Hodgkin's disease, in combination with other agents.

Adult Dose for DTIC-DOME:

Give by IV infusion. Malignant melanoma: 2–4.5mg/kg/day for 10 days, may repeat every 4 weeks; or 250mg/m2 daily for 5 days, may repeat every 3 weeks. Hodgkin's disease (in combination with other drugs): 150mg/m2 daily for 5 days, may repeat every 4 weeks; or 375mg/m2 on day 1, then repeat every 15 days.

Children's Dose for DTIC-DOME:

Not recommended.

Pharmacological Class:

Alkylating agent.

Warnings/Precautions:

Monitor CBCs, platelets; may need to discontinue or suspend therapy if hemopoietic toxicity occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.

Adverse Reactions:

Myelosuppression (eg, leukopenia, thrombocytopenia, anemia), anorexia, nausea, vomiting, flu-like syndrome, alopecia, facial flushing/paresthesia, inj site reactions, anaphylaxis; rare: hepatic necrosis, photosensitivity reactions.

How Supplied:

Vials (20mL)—12